Floradapt Intensive GI

CLINICAL STRAINS™ TARGETING GASTROINTESTINAL HEALTH

Floradapt™ Intensive GI (IGI) is an IP-protected and patented probiotic formula developed for promoting gut health. It provides a significant improvement in the Quality of Life scores thanks to an innovative Mechanism of Action. It supports GI balance and gut homeostasis, supporting regularity. Its formulation contains three clinical strains, and there has been a published clinical trial (randomized, double-blind, placebo-controlled design).

IGI helps maintain healthy gut microbiome and promotes diversity of microbiome. These targeted strains showed a robust capability to survive under harsh gastrointestinal tract (GI) conditions, including exposures to acids and bile. In addition, these specific strains were demonstrated to adhere to intestinal epithelial cells. In terms of GI Tract, the strains showed a particular ability to strengthen the gut barrier and promote gut comfort.

  1. World Gastroenterology Organisation (WGO). Guías prácticas: Probióticos y Prebióticos. 2017.
  2. Drossman, D et al. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150:1262-1279.
  3. Drossman, D et al. Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150:1257-1261.
  4. Rome-IV: Bowel disorders. Gastroenterology 2016; 150: 1393–1407.
  5. Hungin, A.P.S., et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alimentary Pharmacology & Therapeutics, 2003. 17(5): p. 643-650.
  6. Chey et al. Irritable bowel syndrome: a clinical review. JAMA 2015; 313:949-58.
  7. Spiegel et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Inten Med 2004; 164:1773-80.
  8. Fuentes and Christianson. Neurogastroenterol Motil 2016; 28:1613-8.
  9. Wouters et al. The role of mast cells in functional GI disorders. Gut 2016; 65:155-68.
  10. Benson, S., et al. Acute experimental endotoxemia induces visceral hypersensitivity and altered pain evaluation in healthy humans. Pain, 2012. 153: 794-9.
  11. Zolezzi, A. Las Enfermedades Funcionales Gastrointestinales y Roma III. 2007. Rev. Gastroenterol. 27: 177-184.
  12. Jerndal P et al. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil. 2010 Jun;22(6):646-e179.
  13. Zúñiga, V.L.; Llop, E; Suárez, C; et al. I3.1, a new combination of probiotics, improves irritable bowel syndromes-related quality of life. World Journal of Gastroenterology. 20(25):2014.
  14. Patente Internacional. Consultada el 06 de marzo de 2017, disponible en http://patentados.com/patente/compo­sicion-probiotica-uso-tratamiento-inflamacion-intestino.
  15. Espadaler J. Congreso Sociedad Española de Patología Digestiva (SED), Sevilla 2015 (comunicación oral).
  16. Loren V. Workshop Sociedad Española de Probióticos y Prebióticos (SEPyP), Sevilla2016 (poster).
  17. Sharma, M; Devi, M.Probiotics: A Comprehensive Approach toward Health Foods. Critical Reviews in Food Science and Nutrition, 54:537–552 (2014).
  18. Biedermann, L; RoglerEur, G. The intestinal microbiota: its role in health and disease. J Pediatr (2015) 174:151–167.
  19. Tedelind, S., Westberg, F., Kjerrulf, M., and Vidal, A. Anti-in­flammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease, World J Gastroenterol. 2007, 13, 2826-2832.
  20. Vinolo MAR, Rodri­gues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858-76.
  21. Wong JM, de Souza R, Kendall CW et al. Colonic health: fermentation and short-chain fatty acids. J Clin Gastroenterol. 2006;40(3):235-43.
  22. D’Argenio, G., and Mazzacca, G. Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer, Adv Exp Med Biol.(1999) 472, 149-158.
  23. Ishiguro, K., et al. Suppressive action of acetate on interleukin-8 production via tubulin-[alpha] acetylation. Immunol Cell Biol, 2014. 92(7): p. 624-630